409082-02-6

Upstream product

• 64-17-5 ethanol 
• 409082-01-5 ethyl 2-(2-chloro-5-nitrophenyl)acetate 
• 37777-70-1 2-(2-chloro-5-nitrophenyl)acetic acid 
• 2444-36-2 2'-chloro-benzeneacetic acid 
• 89951-56-4 4-chloro-5-hydroxymethyl aniline 
• 80866-80-4 2-chloro-5-nitrobenzyl alcohol 
• 200214-49-9 2-chloro-5-(Boc-amino)benzyl mesylate 
• 200214-50-2 (2-chloro-5-(Boc-amino)phenyl)acetonitrile 
• 200214-48-8 tert-butyl N-[4-chloro-3-(hydroxymethyl)phenyl]carbamate 

Downstream Products

• 200214-52-4 ethyl (2-chloro-5-(Boc-amino)phenyl)acetate 
• 1442472-43-6 1-(4-chloro-3-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)phenyl)-3-phenylurea 
• 1012879-41-2 3-(5-amino-2-chlorophenyl)-1-ethyl-7-(methylamino)-1,6-naphthyridin-2(1H)-one 
• 1012879-40-1 3-(5-amino-2-chlorophenyl)-1-methyl-7-(methylamino)-1,6-naphthyridin-2(1H)-one 
• 1012879-39-8 7-((4-methoxybenzyl)(methyl)amino)-3-(5-amino-2-chlorophenyl)-1-methyl-1,6-naphthyridin-2(1H)-one 
• 1012879-38-7 3-(5-amino-2-chlorophenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one 
• 934477-05-1 C₂₂H₃₀ClN₃O₇S 
• 934477-04-0 2-(5-tert-butoxycarbonylamino-2-chloro-phenyl)-acrylic acid ethyl ester 

Relevant academic research and scientific papers

Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.

DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. The present invention discloses the unexpected utility of compounds that inhibit cKIT kinase across a broad range of c-KIT mutations, including complex occurrences of primary mutations (KIT exon 9 or 11) and secondary KIT mutations (exons 13, 14, 17 and 18) that may arise in individual, refractory GIST patients. Also unexpected is the utility of compounds of the present invention to inhibit the problematic exon 17 D816V c-KIT mutation, for which there is currently no effective therapy.

3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa)

A novel series of cyclic potent, selective, small molecule, thiol-based inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) and the crystal structures of TAFIa inhibitors bound to porcine pancreatic carboxypeptidase B are described. Three series of cyclic arginine and lysine mimetic inhibitors vary significantly in their selectivity against other human basic carboxypeptidases, carboxypeptidase N and carboxypeptidase B. (-)2a displays TAFIa IC50 = 3 nM and 600-fold selectivity against CPN. Inhibition of TAFIa with (rac)2a resulted in dose dependent acceleration of human plasma clot lysis in vitro and was efficacious as an adjunct to tPA in an in vivo rabbit jugular vein thrombolysis model.

Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors

Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compound